Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunologic Effects of CpG ODN Administration to HIV Uninfected and HIV Infected Patients
NCT00100633Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2004
- Primary completion
- Feb 2007
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of agatolimod in hepatitis B (HBV), human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2004; status: completed.
02
Drugs
agatolimod
03
Conditions
hepatitis B (HBV)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00100633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00100633.